Palvella Therapeutics PVLA EBIT

EBIT at other companies

Relay Therapeutics, Inc.RLAY

-$90.82M-18.2%

Viridian Therapeutics, Inc.VRDN

-$126.27M-18.3%

ANI PharmaceuticalsANIP

$40.46M+191%

Arcutis Biotherapeutics, Inc.ARQT

$16.43M+212%

Zevra Therapeutics, Inc.ZVRA

$16.78M+124%

Eton Pharmaceuticals, Inc.ETON

$2.41M+614%

FAQ

What is Palvella Therapeutics's EBIT?

Palvella Therapeutics (PVLA) reported EBIT of -$14.86M in Q1 2026.

How has Palvella Therapeutics's EBIT changed year-over-year?

Palvella Therapeutics's EBIT decreased by 88.7% year-over-year, from -$7.87M to -$14.86M.

What is the long-term trend for Palvella Therapeutics's EBIT?

Over 2 years (2021 to 2025), Palvella Therapeutics's EBIT has grown at a -13.7% compound annual growth rate (CAGR), from -$51.83M to -$38.6M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.